Dr. Alex Wang, Founder and CEO
Alex Wang, Ph.D., is an established executive in the areas of pharmaceutical research and development, business development, product sourcing, in-licensing, project management and senior management leadership. Alex has also demonstrated hands-on and managerial experience in drug target selection and validation, assay development, lead discovery, preclinical and clinical development. Before starting PJ Partner, Alex held senior R&D and BD roles at various companies including Yangzte River Pharmaceutical Group, HUYA Biosciences International and Link Health Group, where he established and leaded 2 NCE1, 1 TCM5 and 1 TCM6. In addition, Alex accomplished 12 medicine transections accumulately.
Alex completed his postdoc training at Canadian National Research Council (CNRC) after he obtained his Ph.D. in Microbiology and Biochemical Pharmacy from China Pharmaceutical University (CPU), MS in Microbiology and Biochemical Pharmacy from CPU and B.S. in Biological Pharmacy from CPU.
Dr. Jian Cui, Vice President
Jian Cui, Ph.D., is in charge of the communication of demestic pharmas and facilitates the transections. He used to work for Sunflower group, and successively served as Deputy Director of R&D Center and General Manager of subsidiary corporation. In his 8 years work experience in Sunflower Group, Jian leaded 8 corporation acquisitions, and licensed in 9 innovative projects. Due to the contribution to the manusfaction process optimization of 3 launched drugs, Jian was awarded the First Prize of Provincial Triditional Chinese Medicine Science and Technology. After leaving Sunflower Group, Jian joined another Chinese listed company，Sinovac, and served as Sales Director till joined PJ Partner.
Jian accomplished his postdoc training in Jilin University after he obtained his Ph.D. from Harbin Medical University.
Team
Ms. Jingjing Luo, Partner
Jingjing Luo, MS, is a clinical pharmacist with additional prescribing authority and specialized in the areas of Diabetes and Teavel Medicine. She has been living in Canada with her family for more than 18 years. She used to serv as Director in Zellers Pharmacy, Shoppers Drug Mart and accumulated great network in Canada and US. Jingjing charges the communication of PJ partner with the customers form Canada and US, and contributes to project evaluation.
Jingjing got her Master degree of Science Biochemistry and Molecular Biology in University of Calgary, Canada, and then, accomplished international Pharmacy Bridging Program 2009 Bredin Institute. She was certificated in Travel Health Since 2019 (issued by International Society of Travel Medicine) and certified Diabetes Educator since 2013 (issued by Canadian Diabetes Educator Certification Board).
Dr. Ting Wang
Ting Wang, Ph.D., has served as CEO of Guangzhou Kaishi Medicine Co., Ltd since June 2021. Ting accumulated more than 30 years work experience in the areas of pharmaceutical research and development, business development, project management and senior management leadership.
Before joining Kaishi Medicine, Ting held senior research and development roles at various companies including Henovcom Bioscience and Welman Pharmaceutical, where he leaded the team developed 6 innovative chemical drugs successfully. As an expert in the domestic biomedical industry, Ting also serves as vice Chairman of the Pharmaceutical Engineering Committee of the Chinese Pharmaceutical Association and Deputy Secretary General of Guangdong Pharmaceutical Association
Ting completed his postdoc training at Gifu Pharmaceutical University (Japan) after he obtained his Ph.D. in Pharmacology from China Pharmaceutical University, MS in Physiology from Department of Biology, Huadong Nomal University and B.S. in Physiology from Huadong Nomal University.
Dr. Shawn Zhang
Shawn Zhang, Ph.D., has served as Senior Vice President of R&D Operations and Ambrx China since April 2021, and previously was Vice President of Research. Shawn is an established executive in the areas of pharmaceutical research and development, business development, product sourcing, in-licensing, project management and senior management leadership. Shawn has also demonstrated hands-on and managerial experience in drug target selection and validation, assay development, lead discovery, preclinical and clinical development. Before his appointment, Shawn held senior research and development roles at various companies including HUYA Biosciences International and Mitsubishi-Tanabe, where he established and led multiple drug projects in oncology, immunology, metabolic diseases and more.
Shawn completed his postdoc training at Cold Spring Harbor Laboratory after he obtained his Ph.D. in Biochemistry from UCSD/Salk Institute, MS in molecular genetics from Institute of Genetics, Chinese Academy of Science and B.S. in biology from Beijing Normal University.
ADVISOR BOARD
